232 related articles for article (PubMed ID: 28551644)
1. Clinical Assessment of Sarcopenia and Changes in Body Composition During Neoadjuvant Chemotherapy for Esophageal Cancer.
Miyata H; Sugimura K; Motoori M; Fujiwara Y; Omori T; Yanagimoto Y; Ohue M; Yasui M; Miyoshi N; Tomokuni A; Akita H; Kobayashi S; Takahashi H; Yano M
Anticancer Res; 2017 Jun; 37(6):3053-3059. PubMed ID: 28551644
[TBL] [Abstract][Full Text] [Related]
2. Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer.
Miyata H; Yano M; Yasuda T; Hamano R; Yamasaki M; Hou E; Motoori M; Shiraishi O; Tanaka K; Mori M; Doki Y
Clin Nutr; 2012 Jun; 31(3):330-6. PubMed ID: 22169459
[TBL] [Abstract][Full Text] [Related]
3. Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy.
Ida S; Watanabe M; Karashima R; Imamura Y; Ishimoto T; Baba Y; Iwagami S; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
Ann Surg Oncol; 2014 Oct; 21(11):3675-9. PubMed ID: 24793436
[TBL] [Abstract][Full Text] [Related]
4. Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.
Motoori M; Fujitani K; Sugimura K; Miyata H; Nakatsuka R; Nishizawa Y; Komatsu H; Miyazaki S; Komori T; Kashiwazaki M; Iwase K; Yano M
Oncology; 2018; 95(5):281-287. PubMed ID: 30149394
[TBL] [Abstract][Full Text] [Related]
5. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer.
Yip C; Goh V; Davies A; Gossage J; Mitchell-Hay R; Hynes O; Maisey N; Ross P; Gaya A; Landau DB; Cook GJ; Griffin N; Mason R
Eur Radiol; 2014 May; 24(5):998-1005. PubMed ID: 24535076
[TBL] [Abstract][Full Text] [Related]
6. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
Tan BH; Brammer K; Randhawa N; Welch NT; Parsons SL; James EJ; Catton JA
Eur J Surg Oncol; 2015 Mar; 41(3):333-8. PubMed ID: 25498359
[TBL] [Abstract][Full Text] [Related]
7. Hematologic toxicities, sarcopenia, and body composition change in breast cancer patients undergoing neoadjuvant chemotherapy.
Jang MK; Park S; Park C; Doorenbos A; Go J; Kim S
Support Care Cancer; 2023 Jun; 31(7):419. PubMed ID: 37354335
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma.
Tanaka Y; Yoshida K; Yamada A; Tanahashi T; Okumura N; Matsuhashi N; Yamaguchi K; Miyazaki T
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1143-52. PubMed ID: 26896963
[TBL] [Abstract][Full Text] [Related]
9. Early Response of Esophageal Cancer to Neoadjuvant Chemotherapy with Docetaxel-Cisplatin-5-Fluorouracil Represents Sensitivity: A Phase II Study.
Matsumoto A; Nishikawa K; Yuda M; Tanaka Y; Tanishima Y; Arakawa Y; Ishibashi Y; Sakuyama T; Omura N; Mitsumori N; Aiba K; Yanaga K
Anticancer Res; 2016 Apr; 36(4):1937-42. PubMed ID: 27069183
[TBL] [Abstract][Full Text] [Related]
10. Sarcopenia and Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
Lyon TD; Frank I; Takahashi N; Boorjian SA; Moynagh MR; Shah PH; Tarrell RF; Cheville JC; Viers BR; Tollefson MK
Clin Genitourin Cancer; 2019 Jun; 17(3):216-222.e5. PubMed ID: 31060857
[TBL] [Abstract][Full Text] [Related]
11. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer.
Awad S; Tan BH; Cui H; Bhalla A; Fearon KC; Parsons SL; Catton JA; Lobo DN
Clin Nutr; 2012 Feb; 31(1):74-7. PubMed ID: 21875767
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer.
Nomura H; Hatogai K; Maki Y; Mochizuki N; Tanaka M; Saito S; Daiko H; Kojima T; Kawasaki T
Support Care Cancer; 2020 Apr; 28(4):1849-1854. PubMed ID: 31342165
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy (FAP) for advanced esophageal cancer.
Shimakawa T; Naritaka Y; Asaka S; Isohata N; Murayama M; Konno S; Yoshimatsu K; Shiozawa S; Katsube T; Ogawa K
Anticancer Res; 2008; 28(4C):2321-6. PubMed ID: 18751413
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
[TBL] [Abstract][Full Text] [Related]
15. Skeletal muscle mass as a predictor of the response to neo-adjuvant chemotherapy in locally advanced esophageal cancer.
Ota T; Ishikawa T; Endo Y; Matsumura S; Yoshida J; Yasuda T; Okayama T; Inoue K; Dohi O; Yoshida N; Sakamoto N; Kamada K; Uchiyama K; Takagi T; Konishi H; Konishi H; Shiozaki A; Fujiwara H; Kishimoto M; Naito Y; Itoh Y
Med Oncol; 2019 Jan; 36(2):15. PubMed ID: 30600347
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of bioelectrical impedance analysis in patients with locoregional muscle invasive or metastatic urothelial carcinoma: a subanalysis of changes in body composition during neoadjuvant systemic chemotherapy.
Miyake M; Owari T; Iwamoto T; Morizawa Y; Hori S; Marugami N; Shimada K; Iida K; Ohnishi K; Gotoh D; Tatsumi Y; Nakai Y; Inoue T; Anai S; Torimoto K; Aoki K; Yoneda T; Tanaka N; Fujimoto K
Support Care Cancer; 2018 Apr; 26(4):1077-1086. PubMed ID: 29022158
[TBL] [Abstract][Full Text] [Related]
17. Randomized study of the clinical effects of ω-3 fatty acid-containing enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer.
Miyata H; Yano M; Yasuda T; Yamasaki M; Murakami K; Makino T; Nishiki K; Sugimura K; Motoori M; Shiraishi O; Mori M; Doki Y
Nutrition; 2017 Jan; 33():204-210. PubMed ID: 27644137
[TBL] [Abstract][Full Text] [Related]
18. Correlation between Skeletal Muscle Mass and Adverse Events of Neoadjuvant Chemotherapy in Patients with Gastric Cancer.
Matsuura N; Motoori M; Fujitani K; Nishizawa Y; Komatsu H; Miyazaki Y; Miyazaki S; Tomokuni A; Komori T; Iwase K
Oncology; 2020; 98(1):29-34. PubMed ID: 31509833
[TBL] [Abstract][Full Text] [Related]
19. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
[TBL] [Abstract][Full Text] [Related]
20. Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.
Zemanova M; Petruzelka L; Pazdro A; Kralova D; Smejkal M; Pazdrova G; Honova H
Dis Esophagus; 2010 Feb; 23(2):160-7. PubMed ID: 19515190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]